short bowel syndrome
Gastroenterology · 2015–2019
4decisions
2medicines
2carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| teduglutide Treatment of patients with Type III (chronic) short bowel syndrome with intestinal failure following major surgery who are dependent on parenteral support. | Mar 2019 | Recommended with restriction | unclear |
| teduglutide Type III (chronic) intestinal failure associated with short bowel syndrome in patients dependent on parenteral support for at least 12 months with stable… | Jul 2018 | Not recommended | input received |
| teduglutide Type III (chronic) intestinal failure associated with short bowel syndrome in patients stable on parenteral support. | Nov 2017 | Not recommended | input received |
| amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides Eosinophilic oesophagitis and severe intestinal malabsorption including short bowel syndrome (Alfamino®); eosinophilic oesophagitis (Alfamino® Junior). | Nov 2015 | Recommended with restriction | none received |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.